Interobserver variability, and visual and quantitative parameters of 123I-FP-CIT SPECT (DaTSCAN) studies

Annals of Nuclear Medicine

Volumn 26, Issue 3, 2012, Pages 234-240

  Papathanasiou, Nikolaos ^a   Rondogianni, Phivi ^a,b   Chroni, Panagiota ^a   Themistocleous, Marios ^a   Boviatsis, Efstathios ^a   Pedeli, Xanthi ^c   Sakas, Damianos ^a   Datseris, Ioannis ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b Medical School ^*  (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

DaTSCAN; Interobserver variability; Parkinson's disease

Indexed keywords

IOFLUPANE I 123;

ADULT; AGED; BASAL GANGLION; CAUDATE NUCLEUS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; KAPPA STATISTICS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OBSERVER VARIATION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; SCINTILLATION CAMERA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL SIGNIFICANCE; STRIATE CORTEX;

EID: 84862670009     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0564-1     Document Type: Review

References (22)

1. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000;15(3):503-10.
2. Kemp PM. Imaging the dopaminergic system in suspected parkinsonism, drug induced movement disorders, and Lewy body dementia. Nucl Med Commun. 2005;26(2):87-96.
3. Scherfler C, Schwarz J, Antonini A, Grosset D, Valldeoriola F, Marek K, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord. 2007;22(9):1229-38.
4. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27.
5. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, et al. Diagnostic value of 123I-ioflupane and 123Iiodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol. 2008;59(5):258-66.
6. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19(10):1175-82.
7. Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (123IIoflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007;22(16):2346-51.
8. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord. 2009;24(4):500-8.
9. Acton PD, Newberg A, Plossl K, Mozley PD. Comparison of region-of-interest analysis and human observers in the diagnosis of Parkinson's disease using [99mTc]TRODAT-1 and SPECT. Phys Med Biol. 2006;51(3):575-85.
10. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13(Suppl 3):2-23.
11. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745-52.
12. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al.EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2 Eur J Nucl Med Mol Imaging. 2010;37(2):443-50.
13. Booij J, Kemp P. Dopamine transporter imaging with [(123)I]FPCIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging. 2008;35(2):424-38.
14. McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6(4):305-13.
15. Tondeur MC, Hambye AS, Dethy S, Ham HR. Interobserver reproducibility of the interpretation of I-123 FP-CIT singlephoton emission computed tomography. Nucl Med Commun. 2010;31(8):717-25.
16. Dickson JC, Tossici-Bolt L, Sera T, Erlandsson K, Varrone A, Tatsch K, et al. The impact of reconstruction method on the quantification of DaTSCAN images. Eur J Nucl Med Mol Imaging. 2010;37(1):23-35.
17. Staff RT, Ahearn TS, Wilson K, Counsell CE, Taylor K, Caslake R, et al. Shape analysis of 123I-N-omega-fluoropropyl-2-betacarbomethoxy- 3beta-(4-iodophenyl) nortropane single-photon emission computed tomography images in the assessment of patients with parkinsonian syndromes. Nucl Med Commun. 2009;30(3):194-201.
18. Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N. SPECT imaging evaluation in movement disorders: far beyond visual assessment. Eur J Nucl Med Mol Imaging. 2011;38(4):764-73.
19. Kagi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81(1): 5-12.
20. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord. 2002;17(1):45-53.
21. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000;15(4):692-8.
22. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt 4):861-70.